Tender Offer - CureVac N.V.

Form Type: SC14D9C

Filing Date: 2025-06-12

Corporate Action: Tender-offer

Type: New

Accession Number: 000110465925058875

Filing Summary: This Schedule 14D-9 filing addresses preliminary communications regarding a planned exchange offer by BioNTech SE to purchase all outstanding ordinary shares of CureVac N.V. for €0.12 per share, set to commence after the Purchase Agreement dated June 12, 2025. The document informs shareholders that the exchange offer has not yet begun and emphasizes the importance of reading future offer materials that will provide further details on the process and conditions. It mentions the necessity for a Tender Offer Statement and Registration Statement to be filed with the SEC when the offer commences and outlines potential risks and uncertainties related to the offer. It also includes information on accessing relevant documents from SEC and CureVac's own communications.